News & Updates
Filter by Specialty:
AI-assisted colonoscopy improves polyp detection
Artificial intelligence (AI)–assisted colonoscopy improves adenoma detection in asymptomatic individuals undergoing colorectal cancer (CRC) screening, a multicentre randomized controlled trial (RCT) has shown.
AI-assisted colonoscopy improves polyp detection
01 Sep 2022RYGB in severe obesity leads to weight loss, hypertension remission
In patients with severe obesity, undergoing either laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (RYGB) resulted in weight loss, according to long-term follow-up of the SLEEVEPASS* trial. However, remission of hypertension was more likely in patients who underwent RYGB compared with LSG.
RYGB in severe obesity leads to weight loss, hypertension remission
29 Aug 2022FMT plus anti-inflammatory diet induces, preserves remission in UC
Patients with mild-to-moderate ulcerative colitis (UC) can achieve deep remission with multidonor faecal microbiota transplantation (FMT) and anti-inflammatory diet, according to an open-label trial. Furthermore, remission can be sustained with anti-inflammatory diet over 1 year.
FMT plus anti-inflammatory diet induces, preserves remission in UC
28 Aug 2022Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE
The triplet combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is as good as dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in terms of efficacy for HIV control but results in better hepatitis B virus (HBV) outcomes in patients with HIV/HBV co-infection, according to results of the phase III ALLIANCE trial presented at IAS 2022.
Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE
24 Aug 2022Infusion-to-injection infliximab switch safe, helps lower risk of IBD relapse for some patients
Switching from intravenous to subcutaneous infliximab appears to be safe and well-accepted, resulting in a reduced risk of relapse in some inflammatory bowel disease (IBD) patients, according to data from the REMSWITCH study.